Vicarius Pharma to offer pre-market entry consulting to emerging innovator companies

 

Vicarius Pharma now offers strategic pre-market entry advice on a fee-for-service basis, allowing partner companies to keep their options open as to how or with whom they will enter the European market. Vicarius combines Regulatory, Medical, Market Access and Commercial expertise in a single point of contact, increasing focus and reducing cost for its partners.

 

KUESSNACHT, SWITZERLAND, 27 May 2019

Vicarius Pharma AG now provides its partners with two sequential service offerings to prepare for and execute the launch of their product in Europe. In a Preparation Phase, Vicarius carries out all necessary pre-submission and pre-approval activities on a fee-for-service basis, through to a decision point on direct entry or partnering. In the Commercial Phase, Vicarius launches and commercializes its partner’s asset on flexible terms, offering unmatched strategic optionality.

 

Vicarius’ highly experienced ready-now European team with expertise in all key areas can manage the go-to-market process through to a go/no-go decision point on direct establishment or partnering. All crucial preparatory activities will be executed in a timely fashion without stretching our partner’s global management bandwidth or focus. During the preparatory consulting phase, our partners keep their European entry options open until the time when organizational build-up has to start.

 

Unlike existing European commercialization options that require innovator companies to either invest significant resources to build their own infrastructure, or to sign away rights and value to a licensing partner, Vicarius’ innovative entry option enables emerging innovator companies to retain control of their assets and extract significantly greater value. Vicarius acts as the innovator’s go-to-market organization for Europe, building a customer-facing organization and commercializing the asset in the innovator’s name, while absorbing launch costs.

 

Vicarius’ European market entry model bridges the gap between traditional go-it-alone and out-licensing strategies. In a partnership with Vicarius, innovator companies retain strategic control over R&D, plus the flexibility to recover at any time the asset and dedicated organization built by Vicarius.

 

About Vicarius

Vicarius Pharma is the premier commercial partner for late-stage specialty, rare/orphan and hospital products in Europe. Our pre-entry consulting offering allows emerging innovator companies to prepare their European market entry based on sound strategic advice on regulatory, pricing and commercial strategies. If they decide to also partner with Vicarius for the European commercialization of their product, they continue to benefit from our vast experience while enjoying unmatched strategic optionality. The company’s executive team are experts in regulatory and pricing strategies, stakeholder/KOL management, building right-sized commercial organizations, and sustained value-creation in Europe. Vicarius Pharma is based in Switzerland.

 

Media Contact

 

Europe

Barbara Fry

Head Corporate Communications

Phone: +41 76 529 05 66

Email: barbara.fry@vicarius-pharma.com

 

 

 

Media

  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
  •